Squire Patton Boggs is pleased to announce the addition of partner Delia Deschaine into the firm’s global Corporate Practice, resident in Washington, DC. She joins from Epstein Becker & Green.
Ms. Deschaine focuses her practice on the healthcare and life sciences industries, representing pharmaceutical companies and biotechnology manufacturers on Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) regulatory matters, transactional matters and in related government investigations. Before entering private practice, she served as an attorney advisor at the US Department of Justice, Drug Enforcement Administration.
“Delia is a dynamic practitioner who brings extensive experience representing pharma and biotech companies on a diverse range of issues that are critical to growing and protecting their businesses,” said Americas Chair of the firm’s Corporate Practice Cip Beredo. “We are committed to augmenting our practice to assist the evolving needs of our clients and are delighted to have someone with Delia’s skillset join our team.”
Ms. Deschaine added, “Joining a firm with Squire’s global scale, deep government experience and connections across the healthcare and life science sectors presents an exciting opportunity to expand the services I can offer my clients and collaborate with new colleagues to grow the firm’s FDA and DEA related offerings. I am excited to join the firm and look forward to the opportunities that lie ahead.”
Ms. Deschaine earned her JD from the University of Maryland Francis King Carey School of Law, and her BA from Manhattanville College.
Source: www.squirepattonboggs.com
